

# Epidemiologic Study of Nosocomial Bacterial Infection of Pediatric Patients at BMA Medical College and Vajira Hospital

Taweewong Tantracheewathorn MD\*,  
Niramorn Vititparapak BSc\*\*, Uraporn Phumisantiphong BSc\*\*

*Presented at the 10<sup>th</sup> Congress of Pediatric Infectious Disease Society of Thailand, Pattaya, Thailand, May 4-5, 2006*

*\* Department of Pediatrics, Bangkok Metropolitan Administration Medical College and Vajira Hospital*

*\*\* Microbiology Unit, Department of Clinical Pathology, Bangkok Metropolitan Administration Medical College and Vajira Hospital*

---

**Background:** Nosocomial infection is a global public health problem, particularly by multi-drug resistant bacteria, increasing morbidity, mortality, and health care costs. The distribution of pathogens and antimicrobial sensitivity patterns change with time and vary among hospitals.

**Objective:** To determine and compare the bacterial pathogens causing nosocomial infections in pediatric patients and their susceptibility patterns between January 2000-December 2002 and January 2003-December 2005.

**Material and Method:** The bacterial pathogens and antimicrobial susceptibilities of children diagnosed as nosocomial infections at BMA Medical College and Vajira Hospital between January 2000 - December 2002 and January 2003- December 2005 were comparatively analyzed.

**Results:** 1,863 and 1,884 isolates were identified in 2000-2002 and 2003-2005, respectively. The common sites of infections were bloodstream (28.6%), lower respiratory tract (15.3%), skin and soft tissue (14.9%), and urinary tract (12.5%). The major isolated gram positive pathogens were *S. aureus*, coagulase negative *Staphylococcus* and *Enterococcus*. The major gram negative pathogens were *E. coli*, *P. aeruginosa*, *K. pneumoniae*, *Enterobacter* spp. and *Acinetobacter* spp. Compared between 2000-2002 and 2003-2005, methicillin resistant *S. aureus* (MRSA) was decreased from 4.3% to 1.5% *P. aeruginosa* from 13.3% to 7.5%, *Enterobacter* spp. from 4.2% to 2.4%, *Serratia* spp. from 1.3% to 0.3%, but methicillin resistant coagulase negative *Staphylococcus* was increased from 5.6% to 10.5% and *K. pneumoniae* from 5.5% to 7.7%, ( $p < 0.05$ ). All gram positive cocci remained sensitive to vancomycin and linezolid. In 2003-2005, gram negative rods were less sensitive to 3<sup>rd</sup> and 4<sup>th</sup> generation cephalosporins and aminoglycosides than in 2000-2002. Sensitivity of gram negative rods to 3<sup>rd</sup> and 4<sup>th</sup> generation cephalosporins were not significantly different except *Enterobacter* spp. and *Serratia* spp., which were more sensitive to 4<sup>th</sup> generation cephalosporin ( $p < 0.05$ ). Most gram negative pathogens (80-100%) were sensitive to ciprofloxacin except *Acinetobacter* spp. (61%). Carbapenems sensitivity were 100% except 92-100% for *Enterobacter* and 67-86% for *P. aeruginosa*, *Acinetobacter* spp. and *Serratia* spp.

**Conclusion:** The bacterial pathogens causing nosocomial infections and their susceptibility patterns change with time, so periodic surveillance are essential as a guide for more proper empirical therapy especially in serious or life threatening infections that need urgent appropriate antibiotics.

**Keywords:** Nosocomial bacterial infection, Epidemiologic study, Children, Susceptibility patterns

*J Med Assoc Thai 2007; 90 (2): 258-65*

**Full text. e-Journal:** <http://www.medassocthai.org/journal>

---

Correspondence to : Tantracheewathorn T, Department of Pediatrics, Bangkok Metropolitan Administration Medical College and Vajira Hospital, Dusit, Bangkok 10300, Thailand. Phone: 0-2244-3158, E-mail: taweewong3@hotmail.com

Nosocomial infection, a global public health problem, particularly caused by multi-drug resistant bacteria, increases morbidity, mortality, duration of hospitalization, health care costs, and work load of public health personnel<sup>(1,2)</sup>. The increased survival of immunocompromised patients, more use of invasive devices and misuse of antimicrobial agents contribute to antimicrobial resistance among bacterial pathogens causing nosocomial infections. Ignorance of infectious control practices increases the transmission of resistant organisms<sup>(3)</sup>.

Although there were previous studies of nosocomial infections and their antimicrobial susceptibility patterns<sup>(4-12)</sup>, the distribution of pathogens and antimicrobial sensitivity change with time and vary among hospitals<sup>(13)</sup>. The objectives of the present study were to determine and compare the bacterial pathogens causing nosocomial infections and their susceptibility patterns in children at BMA Medical College and Vajira Hospital, the tertiary hospital, between 2000-2002 and 2003-2005.

#### Material and Method

The present study was approved by Ethical Committee of Bangkok Metropolitan Administration. Inclusion criteria were children 15 years old or under, diagnosed as nosocomial infection and culture from clinical specimen grew bacteria. Nosocomial bacterial infection was defined as identification of bacteria from specimen with signs and symptoms of the site of infection, occurring more than 48 hours after admission<sup>(1)</sup>. Bacterial isolates without signs and symptoms of the

suspected site of infection (bacterial colonization) were excluded.

Bacterial isolates and susceptibility patterns of pediatric patients with nosocomial bacterial infections admitted at BMA Medical College and Vajira Hospital between January 2000-December 2002 and January 2003-December 2005 were reviewed and comparatively analyzed. Antimicrobial susceptibility tests were performed by the disk diffusion method as recommended by the National Committee for Clinical Laboratory Standards (NCCLS)<sup>(14)</sup>.

#### Statistical analysis

Statistical analysis was performed by Stata version 7.0. Categorical data was expressed as percent and compared between the two groups by Chi-square test. Continuous data were expressed as mean  $\pm$  SD and compared between the two groups by student's t-test. A p-value < 0.05 was considered statistically significant.

#### Results

1,863 and 1,884 isolates were identified in 2000-2002 and 2003-2005, respectively. The most common sites of infections of both periods were bloodstream (28.6%), lower respiratory tract (15.3%), skin and soft tissue (14.9%), and urinary tract (12.5%) respectively as shown in Table 1. The causative pathogens were shown in Table 2. Isolates of gram positive and gram negative bacteria were 751 (40.3%) and 1,112 (59.7%) in 2000-2002 compared with 846 (44.9%) and 1,038 (55.1%) in 2003-2005. The most frequently iso-

**Table 1.** Sites of infections

Sites of infections	2000-2002		2003-2005		p-value
	numbers	%	numbers	%	
Bloodstream	459	28.1	488	29.0	0.57
Lower respiratory tract	248	15.2	260	15.4	0.87
Skin & soft tissue	226	13.9	269	16.0	0.09
Urinary tract	222	13.6	193	11.5	0.07
Surgical wound	124	7.6	115	6.8	0.37
Gastrointestinal tract	122	7.5	158	9.4	0.04*
Eye & ear	78	4.8	72	4.3	0.49
Intra-abdomen	53	3.2	25	1.5	0.001*
CSF	21	1.3	19	1.1	0.60
Others	78	4.8	84	5.0	0.79
Total	1,631	100.0	1,683	100.0	-

\* p < 0.05 by Chi-square test

lated organisms were *E. coli*, *S. aureus*, *P. aeruginosa*, coagulase negative *Staphylococcus* (CoNS) and *K. pneumoniae*. CoNS was increased from 241 isolates (12.9%) to 350 isolates (18.6%) but *S. aureus* was decreased from 318 isolates (17.1%) to 287 isolates (15.2%),  $p < 0.05$ .

Table 3 shows the percentage of susceptibility patterns of gram positive bacteria. In 2000-2002 and 2003-2005, 25.5% and 10.1% of *S. aureus* were methicillin resistant *S. aureus* (MRSA), 43.6% and 56.6% of CoNS were methicillin resistant coagulase negative *Staphylococcus* (MR-CoNS). All gram positive cocci remained sensitive to vancomycin and linezolid. Table 4 shows the percentage of susceptibility patterns of gram negative bacteria. In 2003-2005, most gram negative rods were less sensitive to 3<sup>rd</sup> and 4<sup>th</sup> generation cephalosporins and aminoglycosides than in 2000-2002. Sensitivity of gram negative rods to 3<sup>rd</sup> and 4<sup>th</sup> generation cephalosporins were not significantly different except *Enterobacter* spp. and *Serratia* spp., which were more sensitive to 4<sup>th</sup> generation cephalosporin ( $p < 0.05$ ). Most gram negative pathogens (80-100%) were sensi-

tive to ciprofloxacin except *Acinetobacter* spp. (61%). Sensitivity of gram negative pathogens to carbapenems were 100% except 92-100% for *Enterobacter* and 67-86% for *P.aeruginosa*, *Acinetobacter* spp. and *Serratia* spp. Extended spectrum beta-lactamase enzymes (ESBLs) producing gram negative bacilli (GNB) were markedly increased from 8 isolates (0.4%) in 2000-2002 to 116 isolates (6.2%) in 2003-2005,  $p < 0.05$ . Almost all pathogens in this group were *E. coli*. and *K. pneumoniae*. In addition, they all were all sensitive to carbapenems. ESBLs-producing *E. coli* increased from three isolates (0.9%) to 63 isolates (19.9%) and ESBLs-producing *K. pneumoniae* increased from one isolate (1%) to 43 isolates (29.5%). Between 2003-2005, three isolates (0.2%) of multi-drug resistant-*A. baumannii* were found in infants diagnosed as multi-lobar pneumonia, resisted to nearly all antibiotics except colistin. Treatment with colistin and sulperazon resulted in poor response and death.

#### Discussion

*S. aureus*, CoNS, and gram negative bacilli

**Table 2.** Causative bacteria

Causative bacteria	2000-2002		2003-2005		p-value
	numbers	%	numbers	%	
Gram-positive	751	40.3	846	44.9	-
<i>S. aureus</i> - MSSA	237	12.7	258	13.7	0.37
- MRSA	81	4.3	29	1.5	<0.001*
CoNS - MS-CoNS	136	7.3	152	8.1	0.36
- MR-CoNS	105	5.6	198	10.5	<0.001*
<i>Enterococcus</i>	90	4.8	94	5.0	0.78
Others	102	5.5	115	6.1	-
Gram negative	1,112	59.7	1,038	55.1	-
<i>E. coli</i>	323	17.3	317	16.8	0.68
<i>P. aeruginosa</i>	248	13.3	141	7.5	<0.001*
<i>K. pneumoniae</i>	102	5.5	146	7.7	0.01*
<i>Enterobacter</i> spp.	79	4.2	46	2.4	0.002*
<i>Acinetobacter</i> spp.	70	3.8	84	4.5	0.28
<i>Salmonella</i> spp.	32	1.7	28	1.5	0.63
<i>P. mirabilis</i>	26	1.4	20	1.1	0.41
<i>Serratia</i> spp.	24	1.3	6	0.3	0.001*
<i>Citrobacter</i> spp.	11	0.6	16	0.8	0.46
Others	197	10.6	234	12.4	-
Total	1,863	100.0	1,884	100.0	-

\*  $p < 0.05$  by Chi-square test

MSSA; methicillin sensitive *Staphylococcus aureus*, MRSA; methicillin resistant *Staphylococcus aureus*

MS-CoNS; methicillin sensitive coagulase negative *Staphylococcus*

MR-CoNS; methicillin resistant coagulase negative *Staphylococcus*

**Table 3.** Isolates and percentage of susceptible gram positive organisms

Causative bacteria	Penicillin	Ampicillin	Oxacillin	Gentamicin	Fosfomicin	Fucidic acid	Teicoplanin	Vancomycin	TMP/SMX	Ciprofloxacin	Clindamycin	Erythromycin	Linezolid
MSSA	2000-2002 2003-2005	197 (6) 254 (4)	- -	237 (100) 258 (100)	237 (99) 257 (100)	237 (97) 252 (98)	18 (100) 123 (82)	236 (100) 258 (100)	237 (98) 158 (100)	209 (97) 205 (79)	237 (96) 238 (95)	235 (88) 257 (72)	- 59 (100)
MRSA	2000-2002 2003-2005	0.33 28 (0)	81 (0) 29 (0)	0.11 29 (14)	0.48 29 (69)	0.38 28 (93)	0.04* 17 (88)	81 (100) 29 (100)	0.07 16 (19)	<0.001* 22 (9)	0.60 25 (28)	<0.001* 81 (16)	- 10 (100)
MS-CoNS	2000-2002 2003-2005	- 150 (11)	- 152 (100)	0.47 151 (95)	0.53 150 (47)	0.57 150 (91)	0.26 59 (95)	122 (100) 152 (100)	0.06 96 (70)	0.03* 128 (99)	0.02* 147 (90)	0.52 151 (83)	- 41 (100)
MR-CoNS	2000-2002 2003-2005	0.16 198 (1)	- 198 (0)	0.48 198 (32)	0.001* 198 (51)	0.65 166 (61)	0.02* 186 (88)	105 (100) 186 (100)	0.23 104 (49)	0.52 86 (83)	0.79 103 (59)	0.15 96 (39)	- 39 (100)
<i>Enterococcus</i>	2000-2002 2003-2005	84 (83) 18 (78)	9 (89) 86 (93)	87 (69) 93 (69)	0.25 -	0.27 -	0.01* 82 (99)	90 (100) 94 (100)	0.16 -	0.68 -	0.004* -	0.07 -	- 22 (100)
P		0.62	0.66	1.00	-	-	0.33	-	-	-	-	-	-

\* p < 0.05, number of isolates (%), TMP/SMX; Trimethoprim/sulfamethoxazole

especially *E. coli*, *P. aeruginosa* and *K. pneumoniae* were the predominant pathogens causing nosocomial infections in the present study, similar to previous reports<sup>(5,6,8,11)</sup> with difference in rank order of occurrence. CoNS was the most isolated pathogen in 2003-2005 (18.6%) same as the previous studies of Mongkolrattanothai K et al (33%)<sup>(5)</sup> and Chang MR et al (27.7%)<sup>(8)</sup>. The significantly increased CoNS and MR-CoNS may be a result of an increased survival of very low birth weight (VLBW) preterm infants who have long hospital stay, with intravascular catheters and parenteral nutrition predisposing to bloodstream infection<sup>(15,16)</sup>. CoNS is a common skin inhabitant, so differentiating bacteremia from colonization may be difficult. True bacteremia was suspected in newborns with intravenous catheter or shunt, two or more positive blood cultures of CoNS, signs and symptoms with laboratory data compatible with sepsis, and resolve with appropriate antibiotics or catheter removal<sup>(17)</sup>.

Other gram positive cocci in the present study seemed to be less problematic. *S. aureus* and MRSA were decreased from 17.1% and 4.3% in 2000-2002 to 15.2% and 2.9% in 2003-2005. This may have resulted from the awareness and improvement of infectious control measures, especially hand washing. All gram positive cocci remained sensitive to vancomycin and linezolid. However, worldwide reports of increasing of MRSA<sup>(4,6,7,10,11)</sup>, vancomycin intermediate-resistant *S. aureus* (VISA)<sup>(18,19)</sup>, vancomycin resistant *S. aureus* (VRSA)<sup>(20)</sup> and vancomycin resistant *Enterococcus* (VRE)<sup>(4,9,11)</sup> alarmed the clinicians for the importance of infectious control and proper antibiotic usage.

In 2003-2005, gram negative rods especially *E. coli* and *K. pneumoniae* were less sensitive to 3<sup>rd</sup> and 4<sup>th</sup> generation cephalosporins and aminoglycosides than in 2000-2002 the same as those reported by Chang MR et al<sup>(8)</sup> and Gaynes R et al<sup>(12)</sup>. These may be because of selective pressure resistance from increased use of these groups of antibiotics. However, most gram negative organisms in the present study remained sensitive to ciprofloxacin and carbapenems similar to previous studies<sup>(6,8,10)</sup>. These might be the result of the preserved use of these antibiotics for severe or multi-drug-resistant GNB infections. *Enterobacter* spp. and *Serratia* spp. were resistant to 3<sup>rd</sup> generation cephalosporin (ceftazidime) but remained good sensitive to 4<sup>th</sup> generation cephalosporin (cefepime) and carbapenems, compatible with previous report<sup>(6)</sup>, explained by the production of derepressed chromosomally encoded AmpC cephalosporinase.

Table 4. Isolates and percentage of susceptible gram negative organisms

Causative bacteria	Ampicillin		Amoxicillin/Piperacillin/Clav		Cefotaxime		Cefazidime		Sulperazon		Cefepime		Amikacin		Gentamicin		Netilmicin		Imipenem		Meropenem		Ciprofloxacin		TMP/SMX						
	2000-2002	2003-2005	2000-2002	2003-2005	2000-2002	2003-2005	2000-2002	2003-2005	2000-2002	2003-2005	2000-2002	2003-2005	2000-2002	2003-2005	2000-2002	2003-2005	2000-2002	2003-2005	2000-2002	2003-2005	2000-2002	2003-2005	2000-2002	2003-2005	2000-2002	2003-2005	2000-2002	2003-2005			
<i>E. coli</i>	307 (21)	310 (19)	285 (71)	309 (47)	263 (92)	321 (89)	312 (77)	34 (53)	322 (93)	314 (85)	304 (97)	322 (93)	313 (73)	320 (78)	20 (90)	33 (61)	20 (100)	20 (100)	20 (100)	20 (100)	181 (83)	306 (37)	309 (41)	268 (77)	309 (41)	0.12	0.31	-	-		
<i>P. aeruginosa</i>	0.54	<0.001*	0.21	0.21	<0.001*	<0.001*	0.02*	0.02*	<0.001*	<0.001*	<0.001*	<0.001*	0.14	0.14	0.02*	0.02*	-	-	-	-	197 (86)	137 (90)	-	-	-	-	-	-	-		
<i>K. pneumoniae</i>	89 (0)	132 (0)	80 (65)	37 (27)	80 (73)	101 (70)	145 (68)	135 (80)	102 (75)	102 (75)	94 (89)	102 (75)	102 (72)	102 (72)	23 (35)	23 (35)	23 (100)	23 (100)	23 (100)	23 (100)	80 (90)	88 (59)	131 (60)	139 (86)	139 (86)	139 (86)	139 (86)	139 (86)	139 (86)		
<i>Enterobacter</i> spp.	68 (1)	39 (5)	62 (10)	11 (82)	65 (78)	82 (67)	46 (76)	12 (92)	79 (77)	79 (77)	70 (91)	79 (77)	79 (77)	79 (77)	14 (43)	14 (43)	14 (93)	14 (93)	14 (93)	14 (93)	70 (90)	67 (69)	40 (90)	40 (90)	40 (90)	40 (90)	40 (90)	40 (90)	40 (90)	40 (90)	
<i>Acinetobacter</i> spp.	29 (4)	18 (7)	29 (41)	21 (33)	24 (38)	70 (74)	84 (62)	75 (67)	81 (58)	84 (63)	48 (75)	81 (58)	84 (63)	84 (63)	49 (55)	49 (55)	49 (71)	49 (82)	49 (82)	49 (82)	65 (63)	28 (57)	83 (61)	21 (57)	21 (57)	21 (57)	21 (57)	21 (57)	21 (57)	21 (57)	
<i>Salmonella</i> spp.	32 (84)	28 (39)	21 (95)	25 (76)	32 (100)	32 (100)	26 (96)	0.02*	30 (100)	32 (100)	20 (95)	32 (100)	28 (86)	28 (86)	25 (80)	25 (80)	25 (80)	25 (80)	25 (80)	25 (80)	20 (100)	32 (63)	28 (57)	28 (57)	28 (57)	28 (57)	28 (57)	28 (57)	28 (57)	28 (57)	
<i>P. mirabilis</i>	26 (38)	19 (63)	21 (95)	18 (89)	19 (89)	26 (96)	20 (100)	0.22	23 (96)	26 (100)	20 (95)	26 (100)	26 (80)	26 (80)	20 (95)	20 (95)	20 (85)	20 (85)	20 (85)	20 (85)	17 (88)	26 (42)	19 (63)	19 (63)	19 (63)	19 (63)	19 (63)	19 (63)	19 (63)	19 (63)	
<i>Serratia</i> spp.	0.10	0.49	20 (95)	5 (80)	0.13	0.37	0.04*	0.18	12 (92)	24 (50)	12 (92)	24 (50)	24 (33)	24 (33)	21 (33)	21 (33)	21 (86)	21 (86)	21 (86)	21 (86)	16 (69)	16 (81)	5 (80)	5 (80)	5 (80)	5 (80)	5 (80)	5 (80)	5 (80)	5 (80)	
<i>Citrobacter</i> spp.	11 (0)	16 (0)	9 (33)	16 (88)	11 (27)	10 (90)	16 (88)	0.88	11 (91)	11 (100)	11 (91)	11 (100)	11 (100)	11 (100)	8 (100)	8 (100)	8 (100)	8 (100)	8 (100)	8 (100)	8 (100)	8 (100)	8 (100)	8 (100)	8 (100)	8 (100)	8 (100)	8 (100)	8 (100)	8 (100)	8 (100)
	0.08	0.08	0.08	0.08	0.001*	0.88	0.88	1.00	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13

\* p &lt; 0.05

number of isolates (%), Amoxicillin/Clav; Amoxicillin/Clavulanic acid, Piperacillin/Tazobactam, Sulperazon; Cefoperazone/Sulbactam, TMP/SMX; Trimethoprim/sulfamethoxazole

In the present study, ESBLs-producing bacteria were significantly increased in the latter period. ESBLs production rate was more prevalent in *K. pneumoniae* than *E. coli*, same as previous studies<sup>(6,11,21)</sup>. Although ESBLs are theoretically inhibited by  $\beta$ -lactamase inhibitors, the present study and several studies<sup>(6,10,21)</sup> found that ESBLs producing bacteria were resistant to  $\beta$ -lactam- $\beta$ -lactamase inhibitor combinations but sensitive to carbapenems indicating that carbapenems are the reliable drugs of choice for serious or life-threatening infections caused by ESBLs-producing bacteria.

*Acinetobacter* spp. resisted to several classes of antibiotics. Sensitivity of *Acinetobacter* spp. to carbapenems were 76-80%, and sensitivity to cefoperazone/sulbactam was significantly decreased from 86% in 2000-2002 to 67% in 2003-2005, the same as in previous studies<sup>(6,10)</sup>. Between 2003-2005, there were three isolates of multi-drug resistant-*A. baumannii* (MDR-*A. baumannii*) which resisted to several classes of antibiotics include carbapenems (carbapenem resistant *A. baumannii*, CRAB) except colistin. Nosocomial infections caused by MDR-*A. baumannii*, CRAB, pandrug-resistant *A. baumannii* have been reported in recent years<sup>(22,23)</sup>.

Although emergence of resistance is a result of selective pressure from increased use and misuse of antimicrobial agents, spread of antimicrobial resistant bacteria are caused by spreading of already resistant strains to another patients more than the emergence of new resistant strains in individual cases<sup>(24)</sup>. Periodic surveillance for early detection of new resistant strains combined with other infectious control measures include hand washing, aseptic and sterile technique, appropriate antibiotic use, and education for personnel can reduce the incidence of nosocomial infections.

### Conclusion

The bacterial pathogens causing nosocomial infections and their susceptibility patterns change with time, so periodic surveillance are essential as a guide for more proper empirical therapy especially in serious or life threatening infections that need urgent appropriate antibiotics. Surveillance for new resistant strains combined with other infectious control measures is useful for prevention of nosocomial infections.

### Acknowledgements

The present study was supported by a grant from Vajira Medical Research Fund. The authors wish to thank Miss Busaba Supawattanabodee, Clinical

Epidemiology Unit for statistical analysis.

### References

1. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. *Am J Infect Control* 1988; 16: 128-40.
2. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. *JAMA* 1994; 271: 1598-601.
3. File TM Jr. Overview of resistance in the 1990s. *Chest* 1999; 115(Suppl 3): 3S-8S.
4. Thamlikitkul V, Jintanothaitavorn D, Sathitmethakul R, Vaithayaphichet S, Trakulsomboon S, Danchaivijitr S. Bacterial infections in hospitalized patients in Thailand in 1997 and 2000. *J Med Assoc Thai* 2001; 84: 666-73.
5. Mongkolrattanothai K, Chokephaibulkit K, Kolatat T, Vanprapar N, Chearskul S, Srihapol N, et al. Nosocomial bloodstream infection in pediatric patients: Siriraj Hospital, Bangkok; 1996-1999. *J Med Assoc Thai* 2001; 84: 160-5.
6. Sader HS, Gales AC, Pfaller MA, Mendes RE, Zoccoli C, Barth A, et al. Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY Antimicrobial Surveillance Program. *Braz J Infect Dis* 2001; 5: 200-14.
7. Hsueh PR, Chen ML, Sun CC, Chen WH, Pan HJ, Yang LS, et al. Antimicrobial drug resistance in pathogens causing nosocomial infections at a university hospital in Taiwan, 1981-1999. *Emerg Infect Dis* 2002; 8: 63-8.
8. Chang MR, Carvalho NC, Oliveira AL, Moncada PM, Moraes BA, Asensi MD. Surveillance of pediatric infections in a teaching hospital in Mato Grosso do Sul, Brazil. *Braz J Infect Dis* 2003; 7: 149-60.
9. Wisplinghoff H, Seifert H, Tallent SM, Bischoff T, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. *Pediatr Infect Dis J* 2003; 22: 686-91.
10. Kholy AE, Baseem H, Hall GS, Procop GW, Longworth DL. Antimicrobial resistance in Cairo, Egypt 1999-2000: a survey of five hospitals. *J Antimicrob Chemother* 2003; 51: 625-30.
11. Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-

- 2002). *Diagn Microbiol Infect Dis* 2004; 50: 59-69.
12. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. National Nosocomial Infections Surveillance System. *Clin Infect Dis* 2005; 41: 848-54.
  13. Jones RN. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. *Am J Med* 1996; 100(Suppl 6A): 3S-12S.
  14. National Committee for Clinical Laboratory Standards. Performance for antimicrobial susceptibility testing. 9th information supplement. Document M100-S9. Wayne, PA: NCCLS; 1999.
  15. Freeman J, Goldmann DA, Smith NE, Sidebottom DG, Epstein MF, Platt R. Association of intravenous lipid emulsion and coagulase-negative staphylococcal bacteremia in neonatal intensive care units. *N Engl J Med* 1990; 323: 301-8.
  16. Sidebottom DG, Freeman J, Platt R, Epstein MF, Goldmann DA. Fifteen-year experience with bloodstream isolates of coagulase-negative Staphylococci in neonatal intensive care. *J Clin Microbiol* 1988; 26: 713-8.
  17. Karlowicz MG, Furigay PJ, Croitoru DP, Buescher ES. Central venous catheter removal versus in situ treatment in neonates with coagulase-negative staphylococcal bacteremia. *Pediatr Infect Dis J* 2002; 21: 22-7.
  18. Denis O, Nonhoff C, Byl B, Knoop C, Bobin-Dubreux S, Struelens MJ. Emergence of vancomycin-intermediate *Staphylococcus aureus* in a Belgian hospital: microbiological and clinical features. *J Antimicrob Chemother* 2002; 50: 383-91.
  19. Phongsamart W, Srifeungfung S, Tiensasitorn C, Vanprapar N, Chearskul S, Chokephaibulkit K. The first pediatric case of *Staphylococcus aureus* with heterogenous resistant to vancomycin endocarditis in Thailand. *J Med Assoc Thai* 2005; 88(Suppl 8): S264-S268.
  20. Center for Diseases Control and Prevention. *Staphylococcus aureus* resistant to vancomycin - United States, 2002. *MMWR Morb Mortal Wkly Rep* 2002; 51: 565-7.
  21. Tonkic M, Goic-Barisic I, Punda-Polic V. Prevalence and antimicrobial resistance of extended-spectrum beta-lactamases-producing *Escherichia coli* and *Klebsiella pneumoniae* strains isolated in a university hospital in Split, Croatia. *Int Microbiol* 2005; 8: 119-24.
  22. Bou G, Cervero G, Dominguez MA, Quereda C, Martinez-Beltran J. Characterization of a nosocomial outbreak caused by a multiresistant *Acinetobacter baumannii* strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in *A. baumannii* is not due solely to the presence of beta-lactamases. *J Clin Microbiol* 2000; 38: 3299-305.
  23. Naas T, Levy M, Hirschauer C, Marchandin H, Nordmann P. Outbreak of carbapenem-resistant *Acinetobacter baumannii* producing the carbapenemase OXA-23 in a tertiary care hospital of Papeete, French Polynesia. *J Clin Microbiol* 2005; 43: 4826-9.
  24. Tomasz A. Multiple-antibiotic-resistant pathogenic bacteria. A report on the Rockefeller University Workshop. *N Engl J Med* 1994; 330: 1247-51.

---

## ระบาดวิทยาการติดเชื้อแบคทีเรียในโรงพยาบาลของผู้ป่วยเด็กที่วิทยาลัยแพทยศาสตร์กรุงเทพมหานครและวชิรพยาบาล

ทวิวงศ์ ตันตราชีวรร, นิรมล วิฑิตภัทรภาคย์, อุราภรณ์ ภูมิศานติพงศ์

**ภูมิหลัง:** การติดเชื้อในโรงพยาบาลเป็นปัญหาทางสาธารณสุขทุกแห่งทั่วโลก เชื้อก่อโรคมักเกิดจากเชื้อแบคทีเรียที่ดื้อยาหลายขนาน ก่อให้เกิดภาวะแทรกซ้อนและการเสียชีวิตเพิ่มมากขึ้น อีกทั้งยังสิ้นเปลืองค่าใช้จ่ายในการดูแลรักษา ชนิดของเชื้อก่อโรคและแบบแผนความไวต่อยาปฏิชีวนะเปลี่ยนแปลงตามระยะเวลา และแตกต่างกันในแต่ละโรงพยาบาล

**วัตถุประสงค์:** ศึกษาชนิดของเชื้อแบคทีเรียก่อโรคติดเชื้อในผู้ป่วยเด็กในโรงพยาบาล และแบบแผนความไวต่อยาปฏิชีวนะ ระหว่างมกราคม พ.ศ. 2543 - ธันวาคม พ.ศ. 2545 เปรียบเทียบกับ มกราคม พ.ศ. 2546 - ธันวาคม พ.ศ. 2548

**วัสดุและวิธีการ:** วิเคราะห์เปรียบเทียบชนิดและแบบแผนความไวต่อยาปฏิชีวนะของเชื้อแบคทีเรียก่อโรคในเด็กซึ่งติดเชื้อในโรงพยาบาลที่วิทยาลัยแพทยศาสตร์กรุงเทพมหานครและวชิรพยาบาล ระหว่างมกราคม พ.ศ. 2543 - ธันวาคม พ.ศ. 2545 เปรียบเทียบกับ มกราคม พ.ศ. 2546 - ธันวาคม พ.ศ. 2548

**ผลการศึกษา:** ระหว่าง พ.ศ. 2543- 2545 และ พ.ศ. 2546- 2548 พบผลเพาะเชื้อขึ้นเชื้อจำนวน 1,863 และ 1,884 ตัวอย่างตามลำดับ ตำแหน่งติดเชื้อที่พบบ่อยคือ กระแสเลือด (ร้อยละ 28.6) ทางเดินหายใจส่วนล่าง (ร้อยละ 15.3) ผิวหนังและเนื้อเยื่ออ่อน (ร้อยละ 14.9) และทางเดินปัสสาวะ (ร้อยละ 12.5) เชื้อก่อโรคกรัมบวกที่สำคัญ คือ *S. aureus*, *coagulase negative Staphylococcus*, *Enterococcus* เชื้อก่อโรคกรัมลบที่สำคัญ คือ *E. coli*, *P. aeruginosa*, *K. pneumoniae*, *Enterobacter spp.* and *Acinetobacter spp.* เปรียบเทียบระหว่าง พ.ศ. 2543- 2545 และ พ.ศ. 2546- 2548 พบ *S. aureus* ที่ดื้อยา methicillin ลดลงจากร้อยละ 4.3 เป็นร้อยละ 1.5 *P. aeruginosa* จากร้อยละ 13.3 เป็นร้อยละ 7.5 *Enterobacter spp.* จากร้อยละ 4.2 เป็นร้อยละ 2.4 *Serratia spp.* จากร้อยละ 1.3 เป็นร้อยละ 0.3 แต่พบเชื้อ *coagulase negative Staphylococcus* ที่ดื้อยา methicillin เพิ่มขึ้นจากร้อยละ 5.6 เป็นร้อยละ 10.5 และ *K. pneumoniae* จากร้อยละ 5.5 เป็นร้อยละ 7.7 ( $p < 0.05$ ) เชื้อทรงกลมกรัมบวกทั้งหมดยังไวต่อ vancomycin และ linezolid ใน พ.ศ. 2546- 2548 เชื้อทรงแท่งกรัมลบไวต่อยา cephalosporins กลุ่ม 3 และ 4 และ aminoglycosides ลดลงเมื่อเทียบกับใน พ.ศ. 2543- 2545 เชื้อทรงแท่งกรัมลบไวต่อยา cephalosporins กลุ่ม 3 และ 4 ไม่แตกต่างกัน ยกเว้น *Enterobacter spp.* และ *Serratia spp.* ซึ่งไวต่อยา cephalosporins กลุ่ม 4 มากกว่า ( $p < 0.05$ ) เชื้อก่อโรคกรัมลบส่วนใหญ่ยังไวต่อยา ciprofloxacin ร้อยละ 80-100 ยกเว้น *Acinetobacter spp.* ไวเพียงร้อยละ 61 เชื้อก่อโรคไวต่อยา carbapenems ร้อยละ 100 ยกเว้น *Enterobacter* ไวร้อยละ 92-100 *P.aeruginosa*, *Acinetobacter spp.* และ *Serratia spp.* ไวร้อยละ 67-86

**สรุป:** เชื้อแบคทีเรียที่เป็นสาเหตุของโรคติดเชื้อในโรงพยาบาลและแบบแผนความไวต่อยาปฏิชีวนะเปลี่ยนแปลงตามกาลเวลา ดังนั้นการเฝ้าระวังการเปลี่ยนแปลงเป็นระยะช่วยให้สามารถเลือกใช้ยาปฏิชีวนะในการรักษาเบื้องต้นได้เหมาะสมมากยิ่งขึ้น โดยเฉพาะการติดเชื้อรุนแรงหรือเสี่ยงต่อการเสียชีวิตซึ่งจำเป็นต้องได้รับยาปฏิชีวนะที่เหมาะสมอย่างทันที่